Ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis C 1 genotype in the Republic of Belarus

AIM OF THE STUDY: Aim of the study is to evaluate real-world efficacy of the ombitasvir/ paritaprevir/ ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis C 1 genotype. MATERIAL AND METHODS: The study included 27 patients according to inclusion criteria. Main laboratory studies were...

Descripción completa

Detalles Bibliográficos
Autores principales: Danilau, Dzmitry, Malich, Nadzeya, Litvinchuk, Dzmitry, Karpov, Igor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2017
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649486/
https://www.ncbi.nlm.nih.gov/pubmed/29062907
http://dx.doi.org/10.5114/ceh.2017.70281
_version_ 1783272552040235008
author Danilau, Dzmitry
Malich, Nadzeya
Litvinchuk, Dzmitry
Karpov, Igor
author_facet Danilau, Dzmitry
Malich, Nadzeya
Litvinchuk, Dzmitry
Karpov, Igor
author_sort Danilau, Dzmitry
collection PubMed
description AIM OF THE STUDY: Aim of the study is to evaluate real-world efficacy of the ombitasvir/ paritaprevir/ ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis C 1 genotype. MATERIAL AND METHODS: The study included 27 patients according to inclusion criteria. Main laboratory studies were performed in all patients at the baseline and during the treatment. RESULTS: Efficacy of the antiviral therapy was assessed by measuring the SVR12 and the SVR24 along with measuring of viral load during the treatment. The SVR12 and SVR24 rate was 100% (27/27). DISCUSSION: The results of the treatment were comparable to the results of pivotal, large-scale, randomized clinical trials. There were no serious adverse events during the treatment.
format Online
Article
Text
id pubmed-5649486
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-56494862017-10-23 Ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis C 1 genotype in the Republic of Belarus Danilau, Dzmitry Malich, Nadzeya Litvinchuk, Dzmitry Karpov, Igor Clin Exp Hepatol Original Paper AIM OF THE STUDY: Aim of the study is to evaluate real-world efficacy of the ombitasvir/ paritaprevir/ ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis C 1 genotype. MATERIAL AND METHODS: The study included 27 patients according to inclusion criteria. Main laboratory studies were performed in all patients at the baseline and during the treatment. RESULTS: Efficacy of the antiviral therapy was assessed by measuring the SVR12 and the SVR24 along with measuring of viral load during the treatment. The SVR12 and SVR24 rate was 100% (27/27). DISCUSSION: The results of the treatment were comparable to the results of pivotal, large-scale, randomized clinical trials. There were no serious adverse events during the treatment. Termedia Publishing House 2017-09-25 2017-09 /pmc/articles/PMC5649486/ /pubmed/29062907 http://dx.doi.org/10.5114/ceh.2017.70281 Text en Copyright: © 2017 Clinical and Experimental Hepatology http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Original Paper
Danilau, Dzmitry
Malich, Nadzeya
Litvinchuk, Dzmitry
Karpov, Igor
Ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis C 1 genotype in the Republic of Belarus
title Ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis C 1 genotype in the Republic of Belarus
title_full Ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis C 1 genotype in the Republic of Belarus
title_fullStr Ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis C 1 genotype in the Republic of Belarus
title_full_unstemmed Ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis C 1 genotype in the Republic of Belarus
title_short Ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis C 1 genotype in the Republic of Belarus
title_sort ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis c 1 genotype in the republic of belarus
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649486/
https://www.ncbi.nlm.nih.gov/pubmed/29062907
http://dx.doi.org/10.5114/ceh.2017.70281
work_keys_str_mv AT danilaudzmitry ombitasvirparitaprevirritonavirdasabuvirribavirinfortreatmentofchronichepatitisc1genotypeintherepublicofbelarus
AT malichnadzeya ombitasvirparitaprevirritonavirdasabuvirribavirinfortreatmentofchronichepatitisc1genotypeintherepublicofbelarus
AT litvinchukdzmitry ombitasvirparitaprevirritonavirdasabuvirribavirinfortreatmentofchronichepatitisc1genotypeintherepublicofbelarus
AT karpovigor ombitasvirparitaprevirritonavirdasabuvirribavirinfortreatmentofchronichepatitisc1genotypeintherepublicofbelarus

Ejemplares similares